Natco looking to block Indian patent for Gilead's Sovaldi FiercePharma Gilead believes otherwise; with a 90% cure rate, the company says Sovaldi treatment is cheaper than other alternatives down the line--a new liver alone costs about $300,000 in the U.S., COO John Milligan has noted. But that hasn't stopped the company ... |
